Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziltivekimab in Atherosclerosis and Inflammation
NCT06263244Phase 3Active, not recruiting
- Sponsor
- University of Amsterdam
- Start
- May 2024
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerosis and inflammation comparing Ziltivekimab with Placebo (2 arms). Primary endpoints: Target-to-Background Ratio maximum of coronary arteries at 5.5 months and Monocyte activation marker protein expression at 5.5 months. Started May 2024; status: active, not recruiting.
02
Drugs
ziltivekimab
03
Conditions
atherosclerosisinflammation
Beyond the preview
Go deeper on NCT06263244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06263244.